Cryoablation and Arterial Infusion of SD-101 in Combination With Durvalumab and Tremelimumab
Cryoablation and Arterial Infusion of SD-101 in Combination With Durvalumab and Tremelimumab
Active, not recruiting · NCT06710223 · Registry updated 2026-07-28Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Cryoablation and Arterial Infusion of SD-101 in Combination With Durvalumab and Tremelimumab | Digestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, carcinoma, epithelial neoplasm, hepatocellular carcinoma, liver disorder, neoplasm | Active, not recruiting | Phase 1 | 2026-07-28 | NCT06710223 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Boston Scientific Corporation | 148 |
| TriSalus Life Sciences, Inc. | 7 |
| University of California, San Diego | 337 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| University of California, San Diego | San Diego | United States | 29 |